Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
34 hedge funds and large institutions have $45.5M invested in Cymabay Therapeutics in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 5 closing their positions.
278% more capital invested
Capital invested by funds: $12M → $45.5M (+$33.5M)
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
26% more funds holding
Funds holding: 27 → 34 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.27M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.17M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$2.23M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$1.43M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$1.63M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$353K |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$143K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.49K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$7K |
CBAY Hedge Fund Activity: Q1 2017 in Review
34 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2017, worth a combined $45.5M — up 278% from $12M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CBAY positions and 5 closed out — a net gain of 10 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $3.27M. The largest seller was Kingdon Capital Management, exiting entirely with an estimated $1.63M sold.
- 34 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2017, up from 27 in Q4 2016.
- Funds reported $45.5M of Cymabay Therapeutics stock for Q1 2017, up 278% quarter-over-quarter.
- 15 funds opened new Cymabay Therapeutics positions in Q1 2017 and 5 closed out, a net change of +10 holders.
- The largest Cymabay Therapeutics buyer in Q1 2017 was Adage Capital Partners, an estimated $3.27M added.
- The largest Cymabay Therapeutics seller in Q1 2017 was Kingdon Capital Management, an estimated $1.63M sold.
Based on aggregated 13F filings for Q1 2017.